What is the appropriate treatment for chronic pruritus in a patient with polycythemia vera?

Treatment of Pruritus Associated with Polycythemia Vera

For pruritus in polycythemia vera, initiate selective serotonin reuptake inhibitors (SSRIs) such as paroxetine as first-line pharmacologic therapy, while optimizing disease control with phlebotomy to maintain hematocrit <45% and considering cytoreductive therapy (hydroxyurea or interferon-α) for refractory cases. 1

Stepwise Treatment Algorithm

Initial Management

• Optimize hematocrit control: Maintain hematocrit strictly below 45% through phlebotomy 1. This is the foundation of PV management and may reduce pruritus severity
• Low-dose aspirin: 81-100 mg daily for all patients unless contraindicated 2

Pharmacologic Treatment for Pruritus

First-line options:

• SSRIs (paroxetine): Most effective based on patient-rated outcomes 3. Paroxetine has demonstrated superior efficacy compared to other agents in retrospective analysis
• Antihistamines (hydroxyzine): Also rated highly effective by patients 3, though generally less effective than SSRIs

Second-line options for refractory pruritus:

• Interferon-α: Can effectively treat disabling aquagenic pruritus 1. Consider particularly in younger patients who may need long-term cytoreductive therapy
• JAK2 inhibitors (ruxolitinib): Effective for pruritus relief in patients resistant or intolerant to hydroxyurea 4
• PUVA therapy (psoralens + ultraviolet A): Alternative non-pharmacologic option 1

Emerging option:

• Naltrexone: Novel approach showing immediate and sustained relief in case reports 5. This is an affordable, accessible option for intractable cases, though evidence is limited to case reports

When to Escalate to Cytoreductive Therapy

Progressive disease-related pruritus is an indication for cytoreductive therapy 2. Consider this when:

• Pruritus persists despite optimized hematocrit control and first-line pharmacologic management
• Patient meets high-risk criteria (age ≥60 years or prior thrombosis) 2, 1
• Other progressive symptoms are present (night sweats, fatigue, splenomegaly)

Cytoreductive options:

• Hydroxyurea: 2 g/day for at least 3 months 1
• Interferon-α or pegylated forms: Preferred in younger patients, can reduce JAK2V617F allele burden 1

Important Clinical Considerations

Pathophysiology context: The association between pruritus and low mean corpuscular volume (iron deficiency) and elevated leukocyte counts suggests both iron deficiency and biogenic amines play pathogenetic roles 3. This explains why optimizing disease control through phlebotomy and cytoreduction can improve symptoms.

Common pitfall: Do not rely solely on antihistamines as monotherapy. While they provide some benefit, SSRIs demonstrate superior efficacy for PV-associated pruritus 3.

Quality of life impact: Pruritus affects approximately 33-50% of PV patients 4, 6 and is often aquagenic (water-triggered), making it particularly debilitating. Aggressive symptom management is warranted given the significant morbidity.

Treatment resistance: If pruritus remains refractory after 3 months of hydroxyurea at ≥2 g/day with failure to control symptoms, this meets criteria for hydroxyurea resistance 1, warranting switch to alternative cytoreductive therapy or JAK2 inhibitors.